The Effect of Spironolactone on Control of Pulmonary Hypertension in Patients with Obstructive Pulmonary Disease

Document Type : Original Article (s)

Authors

1 Assistant Professor, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Professor, Department of Cardiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Resident, Department of Cardiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Epidemiologists, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: This study aimed to determine the effect of spironolactone in control of pulmonary hypertension in patients with obstructive pulmonary disease (COPD) who admitted to Alzahra and Chamran hospitals in Isfahan, Iran, during the years 2017-2018.Methods: In a clinical trial study, 80 patients with COPD were selected and randomly divided in to two groups of 40. The first group received spironolactone at a dose of 25 mg, and the second group received routine treatment (without spironolactone). All patients underwent echocardiography and spirometry, and spirometry and electrocardiography parameters were compared between the two groups at the beginning and six months after the start of treatment.Findings: The mean pulmonary arterial pressure was 38.83 ± 6.9 and 39.65 ± 8.8 mmHg (P = 0.560), and 21.73 ± 6.12 and 24.5 ± 7.42 mmHg (P = 0.080), in control and intervention groups, before and 6 months after the treatment, respectively. The mean difference of pulmonary arterial pressure before and after the treatment was 25.4 ± 5.2 and 27.6 ± 5.2 mmHg in control and intervention groups, respectively, and no significant difference were seen between the two groups. Moreover, the improvements of spirometry and echocardiography indices were not statistically different between the two groups.Conclusion: Using spironolactone in patients with COPD has no significant effect on pulmonary hypertension, and spirometry and echocardiography indices, and more studies are needed in this regard.

Keywords

References

  1. Spieth PM, Guldner A, de Abreu MG. Chronic obstructive pulmonary disease. Curr Opin Anaesthesiol 2012; 25(1): 24-9.
  2. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. International variation in the prevalence of COPD (the BOLD Study): A population-based prevalence study. Lancet 2007; 370(9589): 741-50.
  3. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176(6): 532-55.
  4. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349(9064): 1498-504.
  5. Medbo A, Melbye H. What role may symptoms play in the diagnosis of airflow limitation? A study in an elderly population. Scand J Prim Health Care 2008; 26(2): 92-8.
  6. Mannino DM, Buist AS. Global burden of COPD: Risk factors, prevalence, and future trends. Lancet 2007; 370(9589): 765-73.
  7. Lahzami S, Aubert JD. Lung transplantation for C. Swiss Med Wkly 2009; 139(1-2): 4-8.
  8. Rootmensen GN, van Keimpema AR, Looysen EE, van der Schaaf L, de Haan RJ, Jansen HM. The effects of additional care by a pulmonary nurse for asthma and COPD patients at a respiratory outpatient clinic: Results from a double blind, randomized clinical trial. Patient Educ Couns 2008; 70(2): 179-86.
  9. Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G, Mutlu LC, Pehlivan E. Prevalence of COPD: First epidemiological study of a large region in Turkey. Eur J Intern Med 2008; 19(7): 499-504.
  10. Barbera JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 2003; 21(5): 892-905.
  11. Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984; 70(4): 657-62.
  12. Chan KL, Currie PJ, Seward JB, Hagler DJ, Mair DD, Tajik AJ. Comparison of three Doppler ultrasound methods in the prediction of pulmonary artery pressure. J Am Coll Cardiol 1987; 9(3): 549-54.
  13. Voelkel NF, Tuder RM, Weir EK. Pathophysiology of primary pulmonary hypertension: From physiology to molecular mechanisms. In: Rubin LJ, Rich S, editors. Primary pulmonary hypertension. New York, NY: Marcel Dekker, Inc.; 1997. pp. 83–129.
  14. Herve P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, Petitpretz P, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99(3): 249-54.
  15. Maron BA, Opotowsky AR, Landzberg MJ, Loscalzo J, Waxman AB, Leopold JA. Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: A pilot study. Eur J Heart Fail 2013; 15(3): 277-83.
  16. Saxena A. Pulmonary hypertension-"state of the art" management in 2012. Indian Heart J 2012; 64(1): 60-73.
  17. Mandel J, Poch D. In the clinic. Pulmonary hypertension. Ann Intern Med 2013; 158(9): ITC5-16.
  18. Medline Plus. Spironolactone [Online]. [cited 2018 Feb 15]; Available from: URL: https://medlineplus.gov/druginfo/meds/a682627.html
  19. Brittain HG. Analytical Profiles of Drug Substances and Excipients. Academic Press; 2002. p. 309.
  20. MedScape. Spironolactone (Rx) [online]. [cited 2018]; Available from: URL: https://reference. medscape.com/ drug/carospir-aldactone-spironolactone-342407
  21. Maron BA, Waxman AB, Opotowsky AR, Gillies H, Blair C, Aghamohammadzadeh R, et al. Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials). Am J Cardiol 2013; 112(5): 720-5.
  22. Elinoff JM, Rame JE, Forfia PR, Hall MK, Sun J, Gharib AM, et al. A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: Study protocol for a randomized controlled trial. Trials 2013; 14: 91.
Journal of Isfahan Medical School
Volume 36, Issue 502 - Serial Number 502
September and October 2019
Pages 1329-1335

Files

History

  • Receive Date: 10 August 2018
  • Revise Date: 02 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics